<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RIFADIN- rifampin capsule </strong><br><strong>RIFADIN IV- rifampin injection, powder, lyophilized, for solution </strong><br>Sanofi-Aventis U.S. LLC<br></p></div>
<h1>RIFADIN<span class="Sup">®</span><br>(rifampin capsules USP) <br>and <br>RIFADIN<span class="Sup">®</span> IV <br>(rifampin for injection USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of RIFADIN (rifampin capsules USP) and RIFADIN IV (rifampin for injection USP) and other antibacterial drugs, rifampin should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">RIFADIN (rifampin capsules USP) for oral administration contain 150 mg or 300 mg rifampin per capsule. The 150 mg and 300 mg capsules also contain, as inactive ingredients: corn starch, D&amp;C Red No. 28, FD&amp;C Blue No. 1, FD&amp;C Red No. 40, gelatin, magnesium stearate, and titanium dioxide.</p>
<p>RIFADIN IV (rifampin for injection USP) contains rifampin 600 mg, sodium formaldehyde sulfoxylate 10 mg, and sodium hydroxide to adjust pH.</p>
<p>Rifampin is a semisynthetic antibiotic derivative of rifamycin SV. Rifampin is a red-brown crystalline powder very slightly soluble in water at neutral pH, freely soluble in chloroform, soluble in ethyl acetate and in methanol. Its molecular weight is 822.95 and its chemical formula is C<span class="Sub">43</span>H<span class="Sub">58</span>N<span class="Sub">4</span>O<span class="Sub">12</span>. The chemical name for rifampin is either: </p>
<p>3-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin</p>
<p>or</p>
<p>5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,20,22–<br>heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-<span class="Italics">b</span>]furan-1,11(2H)-dione 21-acetate.</p>
<p>Its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=036ab68e-5085-4edc-bd83-784b43d64eab&amp;name=rifadin-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Oral Administration</h2>
<p class="First">Rifampin is readily absorbed from the gastrointestinal tract. Peak serum concentrations in healthy adults and pediatric populations vary widely from individual to individual. Following a single 600 mg oral dose of rifampin in healthy adults, the peak serum concentration averages 7 mcg/mL but may vary from 4 to 32 mcg/mL. Absorption of rifampin is reduced by about 30% when the drug is ingested with food.</p>
<p>Rifampin is widely distributed throughout the body. It is present in effective concentrations in many organs and body fluids, including cerebrospinal fluid. Rifampin is about 80% protein bound. Most of the unbound fraction is not ionized and, therefore, diffuses freely into tissues.</p>
<p>In healthy adults, the mean biological half-life of rifampin in serum averages 3.35 ± 0.66 hours after a 600 mg oral dose, with increases up to 5.08 ± 2.45 hours reported after a 900 mg dose. With repeated administration, the half-life decreases and reaches average values of approximately 2 to 3 hours. The half-life does not differ in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> at doses not exceeding 600 mg daily, and consequently, no dosage adjustment is required. The half-life of rifampin at a dose of 720 mg daily has not been established in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. Following a single 900 mg oral dose of rifampin in patients with varying degrees of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, the mean half-life increased from 3.6 hours in healthy adults to 5.0, 7.3, and 11.0 hours in patients with glomerular filtration rates of 30 to 50 mL/min, less than 30 mL/min, and in anuric patients, respectively. Refer to the <a href="#Warnings">WARNINGS</a> section for information regarding patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
<p>After absorption, rifampin is rapidly eliminated in the bile, and an enterohepatic circulation ensues. During this process, rifampin undergoes progressive deacetylation so that nearly all the drug in the bile is in this form in about 6 hours. This metabolite has antibacterial activity. Intestinal reabsorption is reduced by deacetylation, and elimination is facilitated. Up to 30% of a dose is excreted in the urine, with about half of this being unchanged drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Intravenous Administration</h2>
<p class="First">After intravenous administration of a 300 or 600 mg dose of rifampin infused over 30 minutes to healthy male volunteers (n=12), mean peak plasma concentrations were 9.0 ± 3.0 and 17.5 ± 5.0 mcg/mL, respectively. Total body clearances after the 300 and 600 mg IV doses were 0.19 ± 0.06 and 0.14 ± 0.03 L/hr/kg, respectively. Volumes of distribution at steady state were 0.66 ± 0.14 and 0.64 ± 0.11 L/kg for the 300 and 600 mg IV doses, respectively. After intravenous administration of 300 or 600 mg doses, rifampin plasma concentrations in these volunteers remained detectable for 8 and 12 hours, respectively (see <a href="#table">Table</a>). </p>
<a name="table"></a><table width="100%">
<caption><span>Plasma Concentrations (mean ± standard deviation, mcg/mL)</span></caption>
<col align="left" valign="bottom" width="15%">
<col align="center" valign="bottom" width="15%">
<col align="center" valign="bottom" width="14%">
<col align="center" valign="bottom" width="14%">
<col align="center" valign="bottom" width="14%">
<col align="center" valign="bottom" width="14%">
<col align="center" valign="bottom" width="14%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Rifampin<br>Dosage IV</th>
<th class="Rrule" align="center">30 min</th>
<th class="Rrule" align="center">1 hr</th>
<th class="Rrule" align="center">2 hr</th>
<th class="Rrule" align="center">4 hr</th>
<th class="Rrule" align="center">8 hr</th>
<th class="Rrule" align="center">12 hr</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">300 mg</td>
<td class="Rrule" align="center">8.9±2.9</td>
<td class="Rrule" align="center">4.9±1.3</td>
<td class="Rrule" align="center">4.0±1.3</td>
<td class="Rrule" align="center">2.5±1.0</td>
<td class="Rrule" align="center">1.1±0.6</td>
<td class="Rrule" align="center">&lt;0.4</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">600 mg</td>
<td class="Rrule" align="center">17.4±5.1</td>
<td class="Rrule" align="center">11.7±2.8</td>
<td class="Rrule" align="center">9.4±2.3</td>
<td class="Rrule" align="center">6.4±1.7</td>
<td class="Rrule" align="center">3.5±1.4</td>
<td class="Rrule" align="center">1.2±0.6</td>
</tr>
</tbody>
</table>
<p>Plasma concentrations after the 600 mg dose, which were disproportionately higher (up to 30% greater than expected) than those found after the 300 mg dose, indicated that the elimination of larger doses was not as rapid.</p>
<p>After repeated once-a-day infusions (3 hr duration) of 600 mg in patients (n=5) for 7 days, concentrations of IV rifampin decreased from 5.81 ± 3.38 mcg/mL 8 hours after the infusion on day 1 to 2.6 ± 1.88 mcg/mL 8 hours after the infusion on day 7.</p>
<p>Rifampin is widely distributed throughout the body. It is present in effective concentrations in many organs and body fluids, including cerebrospinal fluid. Rifampin is about 80% protein bound. Most of the unbound fraction is not ionized and therefore diffuses freely into tissues.</p>
<p>Rifampin is rapidly eliminated in the bile and undergoes progressive enterohepatic circulation and deacetylation to the primary metabolite, 25‑desacetyl-rifampin. This metabolite is microbiologically active. Less than 30% of the dose is excreted in the urine as rifampin or metabolites. Serum concentrations do not differ in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> at a studied dose of 300 mg and consequently, no dosage adjustment is required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Pediatrics"></a><a name="section-3.3"></a><p></p>
<h2>Pediatrics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.1"></a><p></p>
<h3>Oral Administration</h3>
<p class="First">In one study, pediatric patients 6 to 58 months old were given rifampin suspended in simple syrup or as dry powder mixed with applesauce at a dose of 10 mg/kg body weight. Peak serum concentrations of 10.7 ± 3.7 and 11.5 ± 5.1 mcg/mL were obtained 1 hour after preprandial ingestion of the drug suspension and the applesauce mixture, respectively. After the administration of either preparation, the t<span class="Sub">1/2</span> of rifampin averaged 2.9 hours. It should be noted that in other studies in pediatric populations, at doses of 10 mg/kg body weight, mean peak serum concentrations of 3.5 mcg/mL to 15 mcg/mL have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.2"></a><p></p>
<h3>Intravenous Administration</h3>
<p class="First">In pediatric patients 0.25 to 12.8 years old (n=12), the mean peak serum concentration of rifampin at the end of a 30 minute infusion of approximately 300 mg/m<span class="Sup">2</span> was 25.9 ± 1.3 mcg/mL; individual peak concentrations 1 to 4 days after initiation of therapy ranged from 11.7 to 41.5 mcg/mL; individual peak concentrations 5 to 14 days after initiation of therapy were 13.6 to 37.4 mcg/mL. The individual serum half-life of rifampin changed from 1.04 to 3.81 hours early in therapy to 1.17 to 3.19 hours 5 to 14 days after therapy was initiated.</p>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.4"></a><p></p>
<h2>Microbiology</h2>
</div>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.5"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> organisms. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></h2>
<p class="First">Organisms resistant to rifampin are likely to be resistant to other rifamycins.</p>
<p><span class="Bold">In the treatment of both <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and the meningococcal carrier state (see <a href="#INDICATIONS">INDICATIONS AND USAGE</a>), the small number of resistant cells present within large populations of susceptible cells can rapidly become predominant. In addition, resistance to rifampin has been determined to occur as single-step mutations of the DNA-dependent RNA polymerase. Since resistance can emerge rapidly, appropriate susceptibility tests should be performed in the event of persistent positive cultures.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.7"></a><p></p>
<h2>Activity <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span>
</h2>
<p class="First">Rifampin has bactericidal activity <span class="Italics">in vitro</span> against slow and intermittently growing <span class="Italics">M <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> </span>organisms.</p>
<p>Rifampin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <a href="#INDICATIONS">INDICATIONS AND USAGE</a> section.</p>
<dl>
<dt> </dt>
<dd>Aerobic Gram-Negative Microorganisms:<br><span class="Italics">Neisseria meningitidis</span>
</dd>
</dl>
<dl>
<dt> </dt>
<dd>"Other" Microorganisms:<br><span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span>
</dd>
</dl>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Underline">but their clinical significance is unknown</span>.</p>
<p>Rifampin exhibits <span class="Italics">in vitro</span> activity against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of rifampin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled trials.</p>
<dl>
<dt> </dt>
<dd>Aerobic Gram-Positive Microorganisms:<br><span class="Italics">Staphylococcus aureus</span> (including Methicillin-Resistant <span class="Italics">S. aureus</span>/MRSA)<br><span class="Italics">Staphylococcus epidermidis</span>
</dd>
</dl>
<dl>
<dt> </dt>
<dd>Aerobic Gram-Negative Microorganisms:<br><span class="Italics">Haemophilus influenzae</span>
</dd>
</dl>
<dl>
<dt> </dt>
<dd>"Other" Microorganisms:<br><span class="Italics">Mycobacterium leprae</span>
</dd>
</dl>
<p>β-lactamase production should have no effect on rifampin activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.8"></a><p></p>
<h2>Susceptibility Testing</h2>
<p class="First">Prior to initiation of therapy, appropriate specimens should be collected for identification of the infecting organism and <span class="Italics">in vitro</span> susceptibility tests.</p>
<p><span class="Italics">In vitro</span> testing for <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> </span>isolates:</p>
<p>Two standardized <span class="Italics">in vitro</span> susceptibility methods are available for testing rifampin against <span class="Italics">M <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> organisms. The agar proportion method (CDC or CLSI<span class="Sup">(1)</span> M24-A) utilizes Middlebrook 7H10 medium impregnated with rifampin at a final concentration of 1.0 mcg/mL to determine <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>. After three weeks of incubation MIC<span class="Sub">99</span> values are calculated by comparing the quantity of organisms growing in the medium containing drug to the control cultures. Mycobacterial growth in the presence of drug, of at least 1% of the growth in the control culture, indicates resistance.</p>
<p>The radiometric broth method employs the BACTEC 460 machine to compare the growth index from untreated control cultures to cultures grown in the presence of 2.0 mcg/mL of rifampin. Strict adherence to the manufacturer's instructions for sample processing and data interpretation is required for this assay.</p>
<p>Susceptibility test results obtained by the two different methods can only be compared if the appropriate rifampin concentration is used for each test method as indicated above. Both procedures require the use of <span class="Italics">M <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> H37Rv ATCC 27294 as a control organism.</p>
<p>The clinical relevance of <span class="Italics">in vitro</span> susceptibility test results for mycobacterial species other than <span class="Italics">M <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> using either the radiometric or the proportion method has not been determined. </p>
<p><span class="Italics">In vitro</span> testing for <span class="Italics">Neisseria meningitidis</span> isolates: </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.8.1"></a><p></p>
<h3>Dilution Techniques</h3>
<p class="First">Quantitative methods that are used to determine <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure uses a standardized dilution method<span class="Sup">2,4 </span>(broth, agar, or microdilution) or equivalent with rifampin powder. The MIC values obtained should be interpreted according to the following criteria for <span class="Italics">Neisseria meningitidis</span>:</p>
<table width="50%">
<col align="left" valign="bottom" width="50%">
<col align="left" valign="bottom" width="50%">
<thead><tr class="First Last">
<th align="left"><span class="Underline">MIC (mcg/mL)</span></th>
<th align="left"><span class="Underline">Interpretation</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">≤ 1     </td>
<td align="left">(S) Susceptible</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">(I) Intermediate</td>
</tr>
<tr class="Last">
<td align="left">≥ 4</td>
<td align="left">(R) Resistant</td>
</tr>
</tbody>
</table>
<p>A report of "susceptible" indicates that the pathogen is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in the blood. A report of "intermediate" indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where the maximum acceptable dose of drug can be used. This category also provides a buffer zone that prevents small-uncontrolled technical factors from causing major discrepancies in interpretation. A report of "resistant" indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected.</p>
<p>Measurement of MIC or minimum bactericidal concentrations (MBC) and achieved antimicrobial compound concentrations may be appropriate to guide therapy in some <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. (See <a href="#CLINICAL">CLINICAL PHARMACOLOGY</a> section for further information on drug concentrations achieved in infected body sites and other pharmacokinetic properties of this antimicrobial drug product.)</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms. The use of these microorganisms does not imply clinical efficacy (see <a href="#INDICATIONS">INDICATIONS AND USAGE</a>); they are used to control the technical aspects of the laboratory procedures. Standard rifampin powder should give the following MIC values: </p>
<table width="60%">
<col align="left" valign="bottom" width="40%">
<col align="left" valign="bottom" width="25%">
<col align="center" valign="bottom" width="35%">
<thead><tr class="First Last">
<th align="left"><span class="Underline">Microorganism</span></th>
<th align="left"></th>
<th align="center"><span class="Underline">MIC (mcg/mL)</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td align="left">ATCC 29213</td>
<td align="center">0.008 – 0.06</td>
</tr>
<tr>
<td align="left"><span class="Italics">Enterococcus faecalis</span></td>
<td align="left">ATCC 29212</td>
<td align="center">1 – 4</td>
</tr>
<tr>
<td align="left"><span class="Italics">Escherichia coli</span></td>
<td align="left">ATCC 25922</td>
<td align="center">8 – 32</td>
</tr>
<tr>
<td align="left"><span class="Italics">Pseudomonas aeruginosa</span></td>
<td align="left">ATCC 27853</td>
<td align="center">32 – 64</td>
</tr>
<tr class="Last">
<td align="left"><span class="Italics">Haemophilus influenzae</span></td>
<td align="left">ATCC 49247</td>
<td align="center">0.25 – 1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.8.2"></a><p></p>
<h3>Diffusion Techniques</h3>
<p class="First">Quantitative methods that require measurement of zone diameters provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">3,4</span> that has been recommended for use with disks to test the susceptibility of microorganisms to rifampin uses the 5 mcg rifampin disk. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for rifampin.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg rifampin disk should be interpreted according to the following criteria for <span class="Italics">Neisseria meningitidis</span>:</p>
<table width="50%">
<col align="left" valign="bottom" width="50%">
<col align="left" valign="bottom" width="50%">
<thead><tr class="First Last">
<th align="left"><span class="Underline">Zone Diameter (mm)</span></th>
<th align="left"><span class="Underline">Interpretation</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">≥ 20</td>
<td align="left">(S) Susceptible</td>
</tr>
<tr>
<td align="left">17–19</td>
<td align="left">(I) Intermediate</td>
</tr>
<tr class="Last">
<td align="left">≤ 16</td>
<td align="left">(R) Resistant</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques.</p>
<p>As with standard dilution techniques, diffusion methods require the use of laboratory control microorganisms. The use of these microorganisms does not imply clinical efficacy (see <a href="#INDICATIONS">INDICATIONS AND USAGE</a>); they are used to control the technical aspects of the laboratory procedures. The 5 mcg rifampin disk should provide the following zone diameters in these quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<table width="60%">
<col align="left" valign="bottom" width="40%">
<col align="left" valign="bottom" width="30%">
<col align="left" valign="bottom" width="30%">
<thead><tr class="First Last">
<th align="left"><span class="Underline">Microorganism</span></th>
<th align="left"></th>
<th align="left"><span class="Underline">Zone Diameter (mm)</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="Italics">S. aureus</span></td>
<td align="left">ATCC 25923</td>
<td align="left">26 – 34</td>
</tr>
<tr>
<td align="left"><span class="Italics">E. coli</span></td>
<td align="left">ATCC 25922</td>
<td align="left">8 – 10</td>
</tr>
<tr class="Last">
<td align="left"><span class="Italics">H. influenzae</span></td>
<td align="left">ATCC 49247</td>
<td align="left">22 – 30</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INDICATIONS"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">In the treatment of both <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></h2>
<p class="First">Rifampin is indicated in the treatment of all forms of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>.</p>
<p>A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER<span class="Sup">®</span>) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span>, the American Thoracic Society, and Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.</p>
<p>Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE<span class="Sup">®</span>) for at least 4 months. Treatment should be continued for longer if the patient is still <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> or culture positive, if resistant organisms are present, or if the patient is HIV positive.</p>
<p>RIFADIN IV is indicated for the initial treatment and retreatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> when the drug cannot be taken by mouth.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Meningococcal Carriers</h2>
<p class="First">Rifampin is indicated for the treatment of asymptomatic carriers of <span class="Italics">Neisseria meningitidis</span> to eliminate meningococci from the nasopharynx. <span class="Bold">Rifampin is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="436621" conceptname="Meningococcal infectious disease">meningococcal infection</span> because of the possibility of the rapid emergence of resistant organisms.</span> (See <a href="#Warnings">WARNINGS</a>.)</p>
<p>Rifampin should not be used indiscriminately, and therefore, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed for establishment of the carrier state and the correct treatment. So that the usefulness of rifampin in the treatment of asymptomatic meningococcal carriers is preserved, the drug should be used only when the risk of meningococcal disease is high.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, rifampin should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">RIFADIN is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to rifampin or any of the components, or to any of the rifamycins.  (See <a href="#Warnings">WARNINGS</a>.)</p>
<p>Rifampin is contraindicated in patients who are also receiving ritonavir-boosted saquinavir due to an increased risk of severe hepatocellular toxicity. (See <a href="#DI">PRECAUTIONS, Drug Interactions</a>.)</p>
<p>Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs, which may result in loss of antiviral efficacy and/or development of viral resistance.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Rifampin has been shown to produce liver dysfunction. Fatalities associated with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> have occurred in patients with liver disease and in patients taking rifampin with other hepatotoxic agents. Patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span> should be given rifampin only in cases of necessity and then with caution and under strict medical supervision. In these patients, careful monitoring of liver function, especially SGPT/ALT and <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/AST should be carried out prior to therapy and then every 2 to 4 weeks during therapy. If signs of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular damage</span> occur, rifampin should be withdrawn.</p>
<p>In some cases, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> resulting from competition between rifampin and bilirubin for excretory pathways of the liver at the cell level can occur in the early days of treatment. An isolated report showing a moderate rise in bilirubin and/or transaminase level is not in itself an indication for interrupting treatment; rather, the decision should be made after repeating the tests, noting trends in the levels, and considering them in conjunction with the patient's clinical condition.</p>
<p>Rifampin has enzyme-inducing properties, including induction of delta amino levulinic acid synthetase. Isolated reports have associated <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> exacerbation with rifampin administration.</p>
<p>The possibility of rapid emergence of resistant meningococci restricts the use of RIFADIN to short-term treatment of the asymptomatic carrier state. <span class="Bold">RIFADIN is not to be used for the treatment of meningococcal disease.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">RIFADIN should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, as <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> management may be more difficult.</p>
<p>Prescribing rifampin in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>For the treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, rifampin is usually administered on a daily basis. Doses of rifampin greater than 600 mg given once or twice weekly have resulted in a higher incidence of adverse reactions, including the "<span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>" (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>), hematopoietic reactions (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, or <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">acute hemolytic anemia</span>), cutaneous, gastrointestinal, and hepatic reactions, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. Recent studies indicate that regimens using twice-weekly doses of rifampin 600 mg plus isoniazid 15 mg/kg are much better tolerated.</p>
<p>Rifampin is not recommended for intermittent therapy; the patient should be cautioned against intentional or accidental interruption of the daily dosage regimen since rare renal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported when therapy was resumed in such cases.</p>
<p>Rifampin has enzyme induction properties that can enhance the metabolism of endogenous substrates including adrenal hormones, thyroid hormones, and vitamin D. Rifampin and isoniazid have been reported to alter vitamin D metabolism. In some cases, reduced levels of circulating 25-hydroxy vitamin D and 1,25-dihydroxy vitamin D have been accompanied by reduced serum calcium and phosphate, and elevated parathyroid hormone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>RIFADIN IV</h2>
<p class="First"><span class="Bold">For intravenous infusion only. Must not be administered by intramuscular or subcutaneous route.</span> Avoid <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> during injection: local irritation and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> due to extravascular infiltration of the infusion have been observed. If these occur, the infusion should be discontinued and restarted at another site.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.3"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including rifampin should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When rifampin is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by rifampin or other antibacterial drugs in the future.</p>
<p><span class="Bold">The patient should be told that rifampin may produce a reddish coloration of the urine, sweat, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, and tears, and the patient should be forewarned of this.</span> Soft contact lenses may be permanently stained. </p>
<p>The patient should be advised that the reliability of oral or other systemic hormonal contraceptives may be affected; consideration should be given to using alternative contraceptive measures.</p>
<p>Patients should be instructed to take rifampin either 1 hour before or 2 hours after a meal with a full glass of water.</p>
<p>Patients should be instructed to notify their physicians promptly if they experience any of the following: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, darkened urine, yellowish discoloration of the skin and eyes, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the joints.</p>
<p>Compliance with the full course of therapy must be emphasized, and the importance of not missing any doses must be stressed.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.4"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Adults treated for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> with rifampin should have baseline measurements of hepatic enzymes, bilirubin, serum creatinine, a complete blood count, and a platelet count (or estimate). Baseline tests are unnecessary in pediatric patients unless a complicating condition is known or clinically suspected.</p>
<p>Patients should be seen at least monthly during therapy and should be specifically questioned concerning symptoms associated with adverse reactions. All patients with abnormalities should have follow-up, including laboratory testing, if necessary. Routine laboratory monitoring for toxicity in people with normal baseline measurements is generally not necessary.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DI"></a><a name="section-7.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Healthy subjects who received rifampin 600 mg once daily concomitantly with saquinavir 1000 mg/ritonavir 100 mg twice daily (ritonavir-boosted saquinavir) developed severe hepatocellular toxicity. Therefore, concomitant use of these medications is contraindicated. (See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5.1"></a><p></p>
<h3>Enzyme Induction</h3>
<p class="First">Rifampin is known to induce certain cytochrome P-450 enzymes. Administration of rifampin with drugs that undergo biotransformation through these metabolic pathways may accelerate elimination of coadministered drugs. To maintain optimum therapeutic blood levels, dosages of drugs metabolized by these enzymes may require adjustment when starting or stopping concomitantly administered rifampin. </p>
<p>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>.)</p>
<p>Rifampin has been reported to accelerate the metabolism of the following drugs: anticonvulsants (e.g., phenytoin), digitoxin, antiarrhythmics (e.g., disopyramide, mexiletine, quinidine, tocainide), oral anticoagulants, antifungals (e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas), levothyroxine, methadone, narcotic analgesics,  progestins, quinine, tacrolimus, theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin. </p>
<p>Patients using oral or other systemic hormonal contraceptives should be advised to change to nonhormonal methods of birth control during rifampin therapy. </p>
<p>Rifampin has been observed to increase the requirements for anticoagulant drugs of the coumarin type. In patients receiving anticoagulants and rifampin concurrently, it is recommended that the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time be performed daily or as frequently as necessary to establish and maintain the required dose of anticoagulant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5.2"></a><p></p>
<h3>Other Interactions</h3>
<p class="First">When the two drugs were taken concomitantly, decreased concentrations of atovaquone and increased concentrations of rifampin were observed.</p>
<p>Concurrent use of ketoconazole and rifampin has resulted in decreased serum concentrations of both drugs. Concurrent use of rifampin and enalapril has resulted in decreased concentrations of enalaprilat, the active metabolite of enalapril. Dosage adjustments should be made if indicated by the patient's clinical condition.</p>
<p>Concomitant antacid administration may reduce the absorption of rifampin. Daily doses of rifampin should be given at least 1 hour before the ingestion of antacids.</p>
<p>Probenecid and cotrimoxazole have been reported to increase the blood level of rifampin.</p>
<p>When rifampin is given concomitantly with either halothane or isoniazid, the potential for hepatotoxicity is increased. The concomitant use of rifampin and halothane should be avoided. Patients receiving both rifampin and isoniazid should be monitored close for hepatotoxicity.</p>
<p>Plasma concentrations of sulfapyridine may be reduced following the concomitant administration of sulfasalazine and rifampin. This finding may be the result of alteration in the colonic bacteria responsible for the reduction of sulfasalazine to sulfapyridine and mesalamine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.6"></a><p></p>
<h2>Drug/Laboratory Interactions</h2>
<p class="First">Cross-reactivity and false-positive urine screening tests for opiates have been reported in patients receiving rifampin when using the KIMS (Kinetic Interaction of Microparticles in Solution) method (e.g., Abuscreen OnLine opiates assay; Roche Diagnostic Systems). Confirmatory tests, such as gas chromatography/<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectrometry, will distinguish rifampin from opiates.</p>
<p>Therapeutic levels of rifampin have been shown to inhibit standard microbiological assays for serum folate and vitamin B<span class="Sub">12</span>. Thus, alternate assay methods should be considered. Transient abnormalities in liver function tests (e.g., elevation in serum bilirubin, alkaline phosphatase, and serum transaminases) and reduced biliary excretion of contrast media used for visualization of the gallbladder have also been observed. Therefore, these tests should be performed before the morning dose of rifampin.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A few cases of accelerated growth of lung carcinoma have been reported in man, but a causal relationship with the drug has not been established.  <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">Hepatomas</span> were increased in female (C3Hf/DP) mice dosed for 60 weeks with rifampicin followed by an observation period of 46 weeks, at 20 to 120 mg/kg (equivalent to 0.1 to 0.5 times the maximum dosage used clinically, based on body surface area comparisons).  There was no evidence of tumorigenicity in male C3Hf/DP mice or in similar studies in BALB/c mice, or in two year studies in Wistar rats.</p>
<p>There was no evidence of mutagenicity in both prokaryotic (<span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhi, Escherichia coli</span>) and eukaryotic (<span class="Italics">Saccharomyces cerevisiae</span>) bacteria, <span class="Italics">Drosophila melanogaster, </span>or ICR/Ha Swiss mice. An increase in chromatid breaks was noted when whole blood cell cultures were treated with rifampin. Increased frequency of chromosomal aberrations was observed <span class="Italics">in vitro</span> in <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> obtained from patients treated with combinations of rifampin, isoniazid, and pyrazinamide and combinations of streptomycin, rifampin, isoniazid, and pyrazinamide. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.8"></a><p></p>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.8.1"></a><p></p>
<h3>Pregnancy–Teratogenic Effects</h3>
<p class="First"><span class="Italics">Category C</span></p>
<p>Rifampin has been shown to be teratogenic in rodents.  Congenital malformations, primarily <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> were increased in the offspring of pregnant rats given rifampin during organogenesis at oral doses of 150 to 250 mg/kg/day (about 1 to 2 times the maximum recommended human dose based on body surface area comparisons).  <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">Cleft palate</span> was increased in a dose-dependent fashion in fetuses of pregnant mice treated at oral doses of 50 to 200 mg/kg (about 0.2 to 0.8 times the maximum recommended human dose based on body surface area comparisons).  Imperfect osteogenesis and embryotoxicity were also reported in pregnant rabbits given rifampin at oral doses up to 200 mg/kg/day (about 3 times the maximum recommended human dose based on body surface area comparisons).  There are no adequate and well-controlled studies of<span class="Bold"> RIFADIN </span>in pregnant women.  Rifampin has been reported to cross the placental barrier and appear in cord blood.  RIFADIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-7.8.2"></a><p></p>
<h3>Pregnancy–Non-Teratogenic Effects</h3>
<p class="First">When administered during the last few weeks of pregnancy, rifampin can cause post-natal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> in the mother and infant for which treatment with vitamin K may be indicated. </p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Because of the potential for tumorigenicity shown for rifampin in animal studies, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.10"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See <a href="#Pediatrics">CLINICAL PHARMACOLOGY–Pediatrics;</a> see also <a href="#Dosage">DOSAGE AND ADMINISTRATION</a>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.11"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of RIFADIN did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Caution should therefore be observed in using rifampin in elderly patients. (See <a href="#Warnings">WARNINGS</a>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> have been noted in some patients. Although <span class="Italics">Clostridium difficile</span> has been shown <span class="Italics">in vitro</span> to be sensitive to rifampin, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been reported with the use of rifampin (and other broad spectrum antibiotics). Therefore, it is important to consider this diagnosis in patients who develop <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in association with antibiotic use. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Hepatic</h2>
<p class="First">Transient abnormalities in liver function tests (e.g., elevations in serum bilirubin, alkaline phosphatase, serum transaminases) have been observed. Rarely, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or a <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>-like syndrome with hepatic involvement and <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Hematologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> has occurred primarily with high dose intermittent therapy, but has also been noted after resumption of interrupted treatment. It rarely occurs during well supervised daily therapy. This effect is reversible if the drug is discontinued as soon as <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> occurs. <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span> and fatalities have been reported when rifampin administration has been continued or resumed after the appearance of <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.</p>
<p>Rare reports of <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> have been observed.</p>
<p><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, and <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span> have been observed.</p>
<p><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> has been reported very rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, inability to concentrate, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, behavioral changes, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span> in extremities, and generalized <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> have been observed.</p>
<p>Psychoses have been rarely reported.</p>
<p>Rare reports of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> have also been observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>Ocular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span> have been observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Menstrual disturbances have been observed.</p>
<p>Rare reports of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> in patients with compromised adrenal function have been observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7"></a><p></p>
<h2>Renal</h2>
<p class="First">Elevations in BUN and serum uric acid have been reported. Rarely, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, <span class="product-label-link" type="condition" conceptid="321414" conceptname="Hemoglobinuria">hemoglobinuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">acute tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been noted. These are generally considered to be <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. They usually occur during intermittent therapy or when treatment is resumed following intentional or accidental interruption of a daily dosage regimen, and are reversible when rifampin is discontinued and appropriate therapy instituted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.8"></a><p></p>
<h2>Dermatologic</h2>
<p class="First">Cutaneous reactions are mild and self-limiting and do not appear to be <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Typically, they consist of <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> with or without a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. More serious cutaneous reactions which may be due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occur but are uncommon.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Occasionally, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139899" conceptname="Pemphigoid">pemphigoid reaction</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4012068" conceptname="Sore mouth">sore mouth</span>, <span class="product-label-link" type="condition" conceptid="441334" conceptname="Glossodynia">sore tongue</span>, and <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> have been observed.</p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.10"></a><p></p>
<h2>Miscellaneous</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> of the face and extremities have been reported. Other reactions which have occurred with intermittent dosage regimens include "<span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>" (such as episodes of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, decrease in blood pressure and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. The "<span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>" may also appear if rifampin is taken irregularly by the patient or if daily administration is resumed after a drug free interval.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and increasing <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> will probably occur within a short time after ingestion; <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> may occur when there is severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. Transient increases in liver enzymes and/or bilirubin may occur. Brownish-red or orange discoloration of the skin, urine, sweat, saliva, tears, and feces will occur, and its intensity is proportional to the amount ingested.</p>
<p><span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Liver enlargement</span>, possibly with <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, can develop within a few hours after severe overdosage; bilirubin levels may increase and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> may develop rapidly. Hepatic involvement may be more marked in patients with prior impairment of hepatic function. Other physical findings remain essentially normal. A direct effect upon the hematopoietic system, electrolyte levels, or acid-base balance is unlikely. </p>
<p>Facial or <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span> has also been reported in pediatric patients. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> were reported in some fatal cases.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Acute Toxicity</h2>
<p class="First">The minimum acute lethal or toxic dose is not well established. However, nonfatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdoses</span> in adults have been reported with doses ranging from 9 to 12 gm rifampin. Fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdoses</span> in adults have been reported with doses ranging from 14 to 60 gm. Alcohol or a history of <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span> was involved in some of the fatal and nonfatal reports. Nonfatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> in pediatric patients ages 1 to 4 years old of 100 mg/kg for one to two doses has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Treatment</h2>
<p class="First">Intensive support measures should be instituted and individual symptoms treated as they arise. The airway should be secured and adequate respiratory exchange established. Since <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are likely to be present, gastric lavage within the first 2 to 3 hours after ingestion is probably preferable to induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>. Following evacuation of the gastric contents, the instillation of activated charcoal slurry into the stomach may help absorb any remaining drug from the gastrointestinal tract. Antiemetic medication may be required to control severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </p>
<p>Active <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> (with measured intake and output) will help promote excretion of the drug. </p>
<p>For severe cases, extracorporeal hemodialysis may be required. If this is not available, peritoneal dialysis can be used along with forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Dosage"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Rifampin can be administered by the oral route or by IV infusion (see <a href="#INDICATIONS">INDICATIONS AND USAGE</a>). IV doses are the same as those for oral. </p>
<p>See <a href="#CLINICAL">CLINICAL PHARMACOLOGY</a> for dosing information in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></h2>
<p class="First">Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral or IV</p>
<p>Pediatric Patients: 10–20 mg/kg, not to exceed 600 mg/day, oral or IV</p>
<p>It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.</p>
<p>Rifampin is indicated in the treatment of all forms of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER<span class="Sup">®</span>) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span>, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.</p>
<p>Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE<span class="Sup">®</span>) for at least 4 months. Treatment should be continued for longer if the patient is still <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> or culture positive, if resistant organisms are present, or if the patient is HIV positive.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.1"></a><p></p>
<h3>Preparation of Solution for IV Infusion</h3>
<p class="First">Reconstitute the lyophilized powder by transferring 10 mL of sterile water for injection to a vial containing 600 mg of rifampin for injection. Swirl vial gently to completely dissolve the antibiotic. The reconstituted solution contains 60 mg rifampin per mL and is stable at room temperature for 24 hours. Prior to administration, withdraw from the reconstituted solution a volume equivalent to the amount of rifampin calculated to be administered and add to 500 mL of infusion medium. Mix well and infuse at a rate allowing for complete infusion within 3 hours. Alternatively, the amount of rifampin calculated to be administered may be added to 100 mL of infusion medium and infused in 30 minutes. </p>
<p>Dilutions in dextrose 5% for injection (D5W) are stable at room temperature for up to 4 hours and should be prepared and used within this time. Precipitation of rifampin from the infusion solution may occur beyond this time. Dilutions in normal saline are stable at room temperature for up to 24 hours and should be prepared and used within this time. Other infusion solutions are not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.2"></a><p></p>
<h3>Incompatibilities</h3>
<p class="First">Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Meningococcal Carriers</h2>
<p class="First">Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.</p>
<p>Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.</p>
<p>Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.1"></a><p></p>
<h3>Preparation of Extemporaneous Oral Suspension</h3>
<p class="First">For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:</p>
<p>RIFADIN 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups–Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories), Syrpalta<span class="Sup">®</span> Syrup (Emerson Laboratories), or Raspberry Syrup (Humco Laboratories).</p>
<ol>
<li>Empty the contents of four RIFADIN 300 mg capsules or eight RIFADIN 150 mg capsules onto a piece of weighing paper.</li>
<li>If necessary, gently crush the capsule contents with a spatula to produce a fine powder.</li>
<li>Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.</li>
<li>Rinse the paper and spatula with 20 mL of one of the above-mentioned syrups, and add the rinse to the bottle. Shake vigorously.</li>
<li>Add 100 mL of syrup to the bottle and shake vigorously.</li>
</ol>
<p>This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3°C) or in a refrigerator (2–8°C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">150 mg maroon and scarlet capsules imprinted "RIFADIN 150."</p>
<p>  Bottles of 30 (NDC 0068-0510-30)</p>
<p>300 mg maroon and scarlet capsules imprinted "RIFADIN 300."</p>
<p>  Bottles of 60 (NDC 0068-0508-60)</p>
<p>  Bottles of 100 (NDC 0068-0508-61)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">Storage: Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Keep tightly closed. Store in a dry place. Avoid excessive heat.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<p class="First">RIFADIN IV (rifampin for injection USP) is available in glass vials containing 600 mg rifampin (NDC 0068-0597-01).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">Storage: Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Avoid excessive heat (temperatures above 40°C or 104°F). Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>References</h1>
<ol>
<li>Clinical Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard CLSI Document M24-A, Vol. 23, No. 18, CLSI, Villanova, PA, 2003.</li>
<li>Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically -- Eighth Edition. Approved Standard CLSI Document M7-A8, Vol. 29, No. 2, CLSI, Villanova, PA, January 2009.</li>
<li>Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests -- Tenth Edition. Approved Standard CLSI Document M2-A10, Vol. 29, No. 1, CLSI, Villanova, PA, January 2009.</li>
<li>Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement, CLSI Document M100-S20, Vol. 30, No. 1, CLSI, Villanova, PA, January 2010.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<h1></h1>
<p class="First">Rifadin capsules are manufactured for:<br>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br>A SANOFI COMPANY</p>
<p>Rifadin IV (rifampin for injection USP) is manufactured by:<br>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br>A SANOFI COMPANY<br></p>
<p>Revised February 2013 </p>
<p>©2013 sanofi-aventis U.S. LLC</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 150mg Bottle Label</h1>
<p class="First">NDC 0068-0510-30</p>
<p><span class="Bold">Rifadin<span class="Sup">®</span><br>150</span>mg</p>
<p><span class="Italics">rifampin capsules USP</span></p>
<p><span class="Bold">30</span> Capsules</p>
<p><span class="Bold">sanofi aventis</span></p>
<div class="Figure"><img alt="Principal Display Panel - 150mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=036ab68e-5085-4edc-bd83-784b43d64eab&amp;name=rifadin-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 300 mg Bottle Label</h1>
<p class="First">NDC 0068-0508-60</p>
<p><span class="Bold">Rifadin<span class="Sup">®</span></span></p>
<p><span class="Italics">rifampin capsules<br>USP</span></p>
<p><span class="Bold">300</span>mg</p>
<p><span class="Bold">60</span> Capsules</p>
<p><span class="Bold">SANOFI</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 300 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=036ab68e-5085-4edc-bd83-784b43d64eab&amp;name=rifadin-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 600 mg Vial Carton</h1>
<p class="First">NDC 0068-0597-01</p>
<p><span class="Bold">Rifadin<span class="Sup">®</span><br>IV</span></p>
<p><span class="Italics">rifampin for<br>injection<br>USP</span></p>
<p><span class="Bold">600</span>mg</p>
<p>For IV<br>Infusion Only</p>
<p><span class="Bold">1</span> Sterile Vial</p>
<p><span class="Bold">SANOFI</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 600 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=036ab68e-5085-4edc-bd83-784b43d64eab&amp;name=rifadin-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIFADIN 		
					</strong><br><span class="contentTableReg">rifampin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0068-0510</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>rifampin</strong> (rifampin) </td>
<td class="formItem">rifampin</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Red No. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Red No. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (maroon and scarlet) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RIFADIN;150</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0068-0510-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062303</td>
<td class="formItem">07/15/1981</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIFADIN 		
					</strong><br><span class="contentTableReg">rifampin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0068-0508</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>rifampin</strong> (rifampin) </td>
<td class="formItem">rifampin</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Red No. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Red No. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (maroon and scarlet) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RIFADIN;300</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0068-0508-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0068-0508-61</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050420</td>
<td class="formItem">05/21/1971</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIFADIN IV 		
					</strong><br><span class="contentTableReg">rifampin injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0068-0597</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>rifampin</strong> (rifampin) </td>
<td class="formItem">rifampin</td>
<td class="formItem">600 mg  in 10 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium formaldehyde sulfoxylate</strong></td>
<td class="formItem">10 mg  in 10 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0068-0597-01</td>
<td class="formItem">10 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050627</td>
<td class="formItem">05/25/1989</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sanofi-Aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">005286822</td>
<td class="formItem">ANALYSIS(0068-0510, 0068-0508), MANUFACTURE(0068-0510, 0068-0508), PACK(0068-0510, 0068-0508), LABEL(0068-0510, 0068-0508)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi-Aventis S.p.A</td>
<td class="formItem"></td>
<td class="formItem">338454274</td>
<td class="formItem">ANALYSIS(0068-0597), MANUFACTURE(0068-0597), PACK(0068-0597), LABEL(0068-0597)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi-Aventis S.p.A</td>
<td class="formItem"></td>
<td class="formItem">378937440</td>
<td class="formItem">API MANUFACTURE(0068-0510, 0068-0508, 0068-0597)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>469b14ef-2403-4313-b246-f95ecb9cd3e8</div>
<div>Set id: 036ab68e-5085-4edc-bd83-784b43d64eab</div>
<div>Version: 9</div>
<div>Effective Time: 20140612</div>
</div>
</div> <div class="DistributorName">Sanofi-Aventis U.S. LLC</div></p>
</body></html>
